Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Deepmatter Group Plc LSE:DMTR London Ordinary Share GB00B29YYY86 ORD 0.01P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 2.20 5,194,281 07:41:02
Bid Price Offer Price High Price Low Price Open Price
2.00 2.40 2.20 2.20 2.20
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Chemicals 1.20 -3.36 -0.43 20
Last Trade Time Trade Type Trade Size Trade Price Currency
17:07:27 O 1,000,000 2.30 GBX

Deepmatter (DMTR) Latest News

More Deepmatter News
Deepmatter Investors    Deepmatter Takeover Rumours

Deepmatter (DMTR) Discussions and Chat

Deepmatter Forums and Chat

Date Time Title Posts
15/1/202113:22DeepMatter 1,026
12/12/202008:41Deepmatter 3

Add a New Thread

Deepmatter (DMTR) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Deepmatter trades in real-time

Deepmatter (DMTR) Top Chat Posts

DateSubject
16/1/2021
08:20
Deepmatter Daily Update: Deepmatter Group Plc is listed in the Chemicals sector of the London Stock Exchange with ticker DMTR. The last closing price for Deepmatter was 2.20p.
Deepmatter Group Plc has a 4 week average price of 1.75p and a 12 week average price of 1.65p.
The 1 year high share price is 3.75p while the 1 year low share price is currently 1.50p.
There are currently 922,397,281 shares in issue and the average daily traded volume is 12,336,017 shares. The market capitalisation of Deepmatter Group Plc is £20,292,740.18.
15/1/2021
11:21
yump: notconvinced has a point - there are bigger players, although they have a limit to the breadth of data they can get in-house. It may be that DMTR is used to enhance efforts in larger businesses. There will always be sharing of course, but this market has different levels of data complexity and reliability requirements.
14/1/2021
11:34
notconvinced: As was said previously DMTR is all about reliable reproduceability, particularly with critical research. Thats why some big players are on the same route, and have the resources to do it in house. Some of the bigger CRO's are already sharing this way without having to bring a Deep Matter solution in to do it for them.
12/1/2021
13:03
the abbot: "Looking to the future And some asking what next, I am minded to revisit the last half year results · Revenue of £0.54m (30 June 2019: £0.22m) · Loss from continuing operations after tax of £1.17m (30 June 2019: loss of £1.62m) · Cash at 30 June 2020 of £2.01m (31 December 2019: £2.61m) Its, certainly interesting to revisit since the last half year report if nothing more than to understand direction of travel for this company. Did you note that in the report the revenue increased by more that 1.4 times, the loss dramatically reduced and the cash was sufficient to continue expansion. Since these results we have also had confirmation that "it has secured contracts with five new major customers over the last two months for its powerful computer aided synthesis design tool, ICSYNTH. In total, ICSYNTH customer numbers have more than doubled through the course of 2020, and the Company has achieved 100% customer renewals, adding to the Group's underlying revenue base. The new customers include some of the world's leading multi-national pharmaceutical, agrisciences, biotech and contract research organisations" Think about that just for a moment, 5 new MAJOR customers in just 2 month, blue chips and 100% contract renewal. Surely that is unheard off in almost any industry to get such a complete adoption and support. We have had - two appointments to the Board. Karen Bach joined as Non-Executive Chair (and immediately bought shares at a premium) and Fraser Benson joined as Chief Financial Officer. DMTR also "signed a three-year contract with Thieme Chemistry, which is part of the Thieme Group, an award-winning international medical and science publisher serving health professionals and students for more than 130 years, for the supply of technical data services and access to the Group's proprietary algorithms." And granted options, the majority at 4p with the balance increasing in 2p increments all the way to 20p!! So what next, I would like and expect to see further adoption, more contracts and am hoping for the biggie, some very public large blue chip adoption, possibly even partnership or even some exciting M&A, certainly Microsoft are on the AL digital chemistry roadmap, it doesn't take much to think that DMTR are a great fit with anyone in this pond. 4 months to build a position up to the next results in May which in my opinion are going to be spectacular and I expect make the 20m market cap look ridiculous. Good luck all, I think its going to get exciting and remind you of the view of Mark Warne our CEO where he said; "In a world where laboratories are required to be digital, to allow chemists to work in a socially distanced environment resulting from the COVID-19 pandemic, the requirement for DigitalGlasswareT82; has accelerated. Laboratories across the world are seeking to modernise lab processes, increase productivity and importantly address the reproducibility crisis in chemistry.""
11/1/2021
08:12
halfpenny: DMTR driving revenue as new contracts flow. Great team with 3p soon and 5p plus as news flow. Great company and Products are special.
10/1/2021
18:43
yump: Seeing as the negatives are going to bang on about low revenue, despite knowing that its a startup... They've just expanded with Thieme. 100% renewals. 5 new customers in a short space of time. So what if its so good that all 5 new customers become renewers and all expand like Thieme ? At least have the decency to knock something overblown. Its ridiculous to knock a startup when its starting up. Why not have the guts to find a company that actually is being hyped up by its own BOD and have a go at that ? Oh, I know why, its because those have flying share prices and knockers would have no credibility.
09/1/2021
11:13
pugugly: re 988. Sounds as though you may be right about being ramped - Need (imo) to see some strong indications that very likely to become cash flow positive - However some can carry on for years at ridiculous levels of revenue to market cap - Just depends on how deep are the pockets of the supportive investors - Some cross the valley of death and emerge profitable - more however leave their bones and backers cash in the valley. Which is DMTR? Will it be like ITX which seems to be emerging (however if next trading update/accounts does not meet market expectation could be a 25%-50% retrenchment) but if good and meets or exceeds expectations a 25%+ upside or like many of the 2000 internet stocks that soared then crashed and burnt - e.g.: Marconi.
09/1/2021
10:55
purchaseatthetop: I see the famous Riddler is pushing DMTR to his cohort and is posting on LSE at the moment: Headlined DMTR progress in last 6 months alone: *Astra/Glaxo form part of the Uk government hub with bases in Oxford, Glasgow and others cities. * Astrazenica had signed an agreement in 2019 work with DMTR to " transform drug design using innovative digital technologies in combination with automation and AI. To get potential new medicines to patients faster" *Cancer Research at Beatson Glasgow to divert energy to tracking C19 and signed a deal with DMTR on 14th April for: the sharing of details of their experiments from anywhere and in real-time A subsequent deployment in China is anticipated to take place later in 2020. *30th April news that Astra are working on a vaccine( perhaps using DMTR technology) ," AstraZeneca has teamed up with the University of Oxford to develop and manufacture a vaccine for coronavirus, in a move that could allow for rapid vaccination" *June : signs collaboration with one of worlds leading companies in the chemicals sector called Waters. *July working with £200bln valued Novartis *Sept confirm record revenues and new customers *Oct :announce they are working with 5 of largest pharmacy and agritech companies *Dec 2020 multi year agreement with a world leading company Theines part of the Thieme Group, an award-winning international medical and science publisher serving health professionals and students for more than 130 years, for the supply of technical data services and access to the Group's proprietary algorithms. Expect a lot of new purchasers to descend like locusts next week. Expect a strong price spike and then some dropping back when Riddler exits with his profits! All IMO only and may be rubbish. I am going to buy more and hold LT
09/1/2021
08:04
halfpenny: DMTR have a great product in high demand with huge prospects and revenue potential. The key for me is the new addition Karen Bach who joined as Non-Executive Chair and Fraser Benson joined as Chief Financial Officer. Karen Bach brings significant public and private technology expertise, particularly focused on helping young technology businesses deliver on their growth potential, with an understanding of the life sciences through her Non-Executive Directorships. The potential is huge...
08/1/2021
08:54
purchaseatthetop: Hi all, Just introducing myself. I bought my first DMTR this morning. I love this kind of share where technology meets internet meets business need. I am expecting a breakout similar to ITX that I am in heavily. GLA
08/1/2021
08:45
halfpenny: DMTR under the Xmas Radar.... DMTR expecting a breakthrough RNS soon. Get ready for the rapid rise. RSI AT A GREAT LEVEL.
Deepmatter share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
DMTR
Deepmatter
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210117 07:55:13